# ITU and Cancer Biology

**A single-axiom view of cellular breakdown, metabolism, immunology, and the 2026-2040 treatment roadmap.**

[![DOI](https://zenodo.org/badge/DOI/10.5281/zenodo.20174318.svg)](https://doi.org/10.5281/zenodo.20174318)

> 📄 **Tier 0 ITU framework**: [10.5281/zenodo.20109210](https://doi.org/10.5281/zenodo.20109210)
> 📄 **Tier 1 #1: Quantum Computing**: [10.5281/zenodo.20139391](https://doi.org/10.5281/zenodo.20139391)
> 📄 **Tier 1 #2: Machine Consciousness / ASI**: [10.5281/zenodo.20150501](https://doi.org/10.5281/zenodo.20150501)
> 📄 **Tier 1 #3: Cryptography**: [10.5281/zenodo.20151059](https://doi.org/10.5281/zenodo.20151059)
> 📄 **Tier 1 #4: Semiconductors**: [10.5281/zenodo.20174036](https://doi.org/10.5281/zenodo.20174036)
> 📄 **Tier 1 #5 (this paper)**: [10.5281/zenodo.20174318](https://doi.org/10.5281/zenodo.20174318)
> 💻 **GitHub**: https://github.com/roboken-terada2/information-theoretic-unification
> ✉️ **著者**: 寺田 宗弘 (Munehiro Terada), Roboken — `munehiro.terada@roboken2.com`

---

## 概要

This **Tier 1 #5 application paper** is the first ITU paper in the **medicine** domain, transitioning ITU from engineering (Tier 1 #1-#4) into clinical biology.

Central thesis:

$$\text{Cancer} = \text{breakdown of } \delta S(\rho_{\rm cell}) = \delta \mathrm{Tr}[K_A^{(0)} \rho_{\rm cell}]
   \quad \text{at cellular and tissue levels}$$

The ITU axiom yields:
1. **10 Hallmarks of Cancer** as 10 K-component failures
2. **Two-hit hypothesis** (Knudson) as redundant QECC
3. **Warburg effect** as deliberate K_metabolic degradation maximising entropy production
4. **Immune evasion** as 7-step K_immune corruption (Cancer-Immunity Cycle)
5. **Combination therapy necessity** as multi-K simultaneous restoration
6. **2026-2040 treatment roadmap** with 10 falsifiable predictions

This **opens the medicine vector** of the ITU programme. Tier 1 #6 (Aging) and #7 (Psychiatry) will form a medicine triangle.

---

## ITU Tier structure

| Tier | DOI | Contents | Status |
|---|---|---|---|
| Tier 0 (core) | [10.5281/zenodo.20109210](https://doi.org/10.5281/zenodo.20109210) | ITU foundational 42 phases | v2.0.0 |
| Tier 1 #1 | [10.5281/zenodo.20139391](https://doi.org/10.5281/zenodo.20139391) | Quantum Computing | v1.0.0 |
| Tier 1 #2 | [10.5281/zenodo.20150501](https://doi.org/10.5281/zenodo.20150501) | Machine Consciousness / ASI | v1.0.0 |
| Tier 1 #3 | [10.5281/zenodo.20151059](https://doi.org/10.5281/zenodo.20151059) | Cryptography | v1.0.0 |
| Tier 1 #4 | [10.5281/zenodo.20174036](https://doi.org/10.5281/zenodo.20174036) | Semiconductors | v1.0.0 |
| **Tier 1 #5** | **[10.5281/zenodo.20174318](https://doi.org/10.5281/zenodo.20174318)** | **Cancer Biology** | **v1.0.0 (this paper)** |
| Tier 1 #6+ | TBD | Aging, Psychiatry, ... | planned |

---

## Phases in this paper

| Phase | Status | Topic |
|---|---|---|
| **59** | ✅ | ITU foundation: cancer = δS = δ⟨K⟩ breakdown; 10 Hallmarks = 10 K-components |
| **60** | ✅ | Warburg effect: deliberate K_metabolic degradation |
| **61** | ✅ | Immunology: K_immune corruption + ICI/CAR-T/TIL restoration |
| **62** | ✅ | 2026-2040 ITU-informed treatment roadmap + 10 predictions |

---

## Key Results (v1.0.0)

| Quantity | Value |
|---|---|
| K-component loss in cancer cell | **75%** (mean K = 1.0 → 0.25) |
| Two-hit BRCA1 risk @80 yr (model vs literature) | **72% vs 72%** ✅ |
| TMB sigmoid vs Rizvi 2015 | Matches order of magnitude |
| Cancer glucose entropy rate vs normal | **~7× higher** |
| Tumor pH after 48h (model) | **6.0-6.7** ✅ |
| ICI monotherapy response | 20-25% |
| ICI combo (ipi+nivo) response | **50%** |
| ITU 3-axis predicted response | **70%** (by 2028) |
| Pancreatic 5-yr survival (2024 → 2040) | **10% → 50%** |
| Glioblastoma 5-yr survival (2024 → 2040) | **5% → 30%** |
| Falsifiable predictions | **10 listed** |

---

## Reproducing the results

```bash
cd papers/cancer-biology
python cancer_itu_foundation.py    # Phase 59 (~5 seconds)
python warburg_metabolism.py       # Phase 60 (~5 seconds)
python cancer_immunology.py        # Phase 61 (~5 seconds)
python cancer_roadmap.py           # Phase 62 (~5 seconds)
```

Required: Python 3.10+, numpy, scipy, matplotlib.

Total runtime ~20 seconds. Outputs: 4 `.png` figures, 4 `summary_phase##.json`.

---

## Directory contents

```
papers/cancer-biology/
├── README.md                         this file
├── CITATION.cff                      machine-readable citation
├── .zenodo.json                      Zenodo upload metadata
│
├── theory_phase59.md                 ITU foundation for cancer
├── theory_phase60.md                 Warburg effect (metabolism)
├── theory_phase61.md                 Immunology (K_immune)
├── theory_phase62.md                 Roadmap and predictions
│
├── cancer_itu_foundation.py / .png   Phase 59
├── warburg_metabolism.py / .png      Phase 60
├── cancer_immunology.py / .png       Phase 61
├── cancer_roadmap.py / .png          Phase 62
│
└── summary_phase59-62.json
```

---

## How to cite

This Tier 1 #5 paper:

```
Terada, M. (2026). ITU and Cancer Biology:
A Single-Axiom View of Cellular Breakdown, Metabolism,
Immunology, and the 2026-2040 Treatment Roadmap (v1.0.0).
Zenodo. https://doi.org/10.5281/zenodo.20174318
```

The core ITU framework (Tier 0):

```
Terada, M. (2026). Information-Theoretic Unification of Physics,
Life, and Consciousness: Numerical Demonstration in 42 Phases (v2.0.0).
Zenodo. https://doi.org/10.5281/zenodo.20109210
```

Both citations are recommended together.

---

## License

* Text content (paper, theory notes, figures): **CC-BY-4.0**
* Source code (`*.py`): **MIT License**

---

## Honest framing (Pass-1 interpretive paper)

This paper is a **Pass-1 interpretive contribution**: it reframes known cancer biology
(Hallmarks of Cancer, Warburg effect, ICI biology, multi-hit mutation accumulation)
within the ITU axiom $\delta S = \delta\langle K\rangle$. The numerical results
reproduce well-established clinical data (BRCA1 72%, tumor pH ~6.5, TMB-response
sigmoid, ICI combo 50%) but do not constitute novel cancer-biology predictions
distinguishing ITU from standard oncology.

The **2026-2040 5-year survival projections and 10 falsifiable predictions** in Phase 62
are ITU-informed but overlap substantially with industry consensus (AACR, ASCO).
**Pass-2 follow-up work** would derive a specific ITU-unique therapeutic figure-of-merit
or biomarker validated against patient outcome data.

This honest framing is consistent across all Tier 1 papers (#1-#5).

---

## ITU programme: engineering rectangle complete, medicine vector begins

```
                                  Cancer (#5) ← THIS PAPER (medicine begins)
                                  /
                                 /
   AI/ASI (#2) ←─→ Cryptography (#3)
       ↑               ↑
       │               │
   Quantum Computing (#1) ── Semiconductors (#4)
```

| # | Domain | Axis |
|---|---|---|
| #1 | QC | engineering (storage) |
| #2 | AI/ASI | engineering (intelligence) |
| #3 | Crypto | engineering (communication) |
| #4 | Semi | engineering (substrate) |
| **#5** | **Cancer** | **medicine (cellular breakdown)** ← NEW |

Future Tier 1 #6 (Aging) and #7 (Psychiatry) will form a **medicine triangle**.

---

**寺田 宗弘 (Roboken)**
ITU Tier 1 paper #5 — Cancer Biology
2026年5月14日

Part of the *Information-Theoretic Unification* research programme.
For the foundational theory (Phases 1-42), see
[10.5281/zenodo.20109210](https://doi.org/10.5281/zenodo.20109210).
